ABSTRACT Introduction: Five NK-1 RA formulations are commercially available to treat the
delayed phase of chemotherapy-induced nausea and vomiting (CINV) occurring between …

To examine pharmacologic and clinical characteristics of neurokinin 1 (NK1)-receptor
antagonists (RAs) for preventing chemotherapy-induced nausea and vomiting (CINV) …

Chemotherapy-induced nausea and vomiting is a significant clinical issue which affects
patient's quality of life and treatment decisions. Significant improvements in the control of …

Despite progress in the area of supportive care in oncology in the last two decades, nausea
and vomiting continue to be significant side effects of cancer therapy. These symptoms can …

Background Neurokinin (NK) 1 receptor antagonists (RAs), administered in combination with
a 5-hydroxytryptamine-3 (5-HT3) RA and dexamethasone (DEX), have demonstrated clear …

Introduction: The addition of neurokinin-1 receptor antagonists (NK1RAs) to standard
prophylaxis of 5-hydroxytryptamine-3 RA (5-HT3RA) plus dexamethasone more effectively …

Significant progress has been made in the development of effective, convenient, and well-
tolerated means to prevent nausea and vomiting associated with cancer chemotherapy …

This paper reviews the clinical profile of the neurokinin-1 (NK1) receptor antagonist
aprepitant, the first approved antiemetic in its class, developed for use in the prevention of …

Knowledge of the involvement of the neurokinin substance P in emesis has led to the
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …

Background: Nausea and vomiting is one of the most feared side effects of chemotherapy;
however, in the past 20 years, a better understanding of the pathophysiology of …